ASGCT 2021 and Cell Therapy View overview page

2:08
Challenges in translating iPSC-based AMD therapies to the clinic
Masayo Takahashi • 26 May 2021
5:28
T cell and HSC gene editing for the treatment of Hyper-IgM Type 1
Valentina Vavassori • 27 May 2021
1:32
The potential of oncolytic adenoviral vectors
Margarita Romanenko • 13 May 2021
4:17
miCAR: combining microRNA gene silencing with CAR expression
Marco Alessandrini • 20 May 2021
4:37
Developing CAR T-cell therapy for HIV
Marco Alessandrini • 20 May 2021
5:05
Hypoimmunogenic iPSCs: avoiding immune rejection
Sonja Schrepfer • 27 May 2021
2:01
Cardiosphere-derived cells in myocardial regeneration
Linda Marban • 19 May 2021
5:31
CRISPR-Cas9 gene-edited HSPCs for Friedreich’s ataxia
Stephanie Cherqui • 17 May 2021
1:58
Highlights from ASGCT 2021: iPSCs & the immunological barrier
Sonja Schrepfer • 27 May 2021
3:07
Horizon scanning in anti-CD19 CAR T-cell therapy
Marco Alessandrini • 20 May 2021
3:38
Avoiding immune rejection of allogeneic iPSCs
Sonja Schrepfer • 27 May 2021
3:32
iPSC-derived RPE for macular degeneration
Masayo Takahashi • 26 May 2021
1:40
DARIC33: CAR T with an on/off switch
Jacob Appelbaum • 12 May 2021
1:19
Exosomes: a game changer in mRNA-based therapeutics?
Linda Marban • 19 May 2021
The content of VJRegenMed is intended for healthcare professionals